ANGO Stock Analysis: AngioDynamics | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 639m USD | 12M Return: 39.3% | US03475V1017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.80M
Qual. Beats: 0
Rev. Trend: -31.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AngioDynamics (NASDAQ: ANGO) is a U.S.-based medical technology company founded in 1988 and headquartered in Latham, New York, that designs, manufactures, and sells devices for peripheral vascular disease, oncology, and surgical applications across domestic and international markets. Its product portfolio spans atherectomy and thrombectomy systems (Auryon, AlphaVac, AngioVac), tumor ablation platforms (NanoKnife IRE, Solero Microwave), and a range of peripheral and access products such as angiographic catheters, micro-access kits, drainage catheters, and the VenaCure EVLT laser system for venous disease.
As a small-cap (~$512M market cap) player in the Health Care Equipment sub-industry, ANGO operates in a highly competitive medical devices sector that includes much larger incumbents such as Medtronic, Boston Scientific, and Penumbra, where success depends on clinical differentiation, regulatory approvals, and physician adoption of newer technologies like IRE and mechanical thrombectomy.
- Auryon atherectomy system drives vascular segment revenue growth
- AlphaVac thrombectomy commercialization accelerates thrombus management adoption
- NanoKnife IRE ablation expands oncology procedure footprint
| Net Income: -36.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 5.40 > 1.0 |
| NWC/Revenue: 27.70% < 20% (prev 31.50%; Δ -3.80% < -1%) |
| CFO/TA 0.01 > 3% & CFO 3.09m > Net Income -36.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.5m) vs 12m ago 1.32% < -2% |
| Gross Margin: 54.62% > 18% (prev 53.92%; Δ 0.71% > 0.5%) |
| Asset Turnover: 117.0% > 50% (prev 104.4%; Δ 12.59% > 0%) |
| Interest Coverage Ratio: -120.4 > 6 (EBIT TTM -36.0m / Interest Expense TTM 299k) |
| A: 0.33 (Total Current Assets 163.4m - Total Current Liabilities 74.7m) / Total Assets 267.2m |
| B: -1.74 (Retained Earnings -465.9m / Total Assets 267.2m) |
| C: -0.13 (EBIT TTM -36.0m / Avg Total Assets 273.7m) |
| D: 1.77 (Book Value of Equity 170.8m / Total Liabilities 96.3m) |
| Altman-Z'' = -2.53 = D |
| DSRI: 1.02 (Receivables 48.3m/43.1m, Revenue 320.2m/292.5m) |
| GMI: 0.99 (GM 53.92% / 54.62%) |
| AQI: 1.01 (AQ_t 0.29 / AQ_t-1 0.28) |
| SGI: 1.09 (Revenue 320.2m / 292.5m) |
| TATA: -0.15 (NI -36.7m - CFO 3.09m) / TA 267.2m) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of September 11, 2026, the stock is trading at USD 15.24 with a total of 238,744 shares traded. Over the past week, the price has changed by -2.43%, over one month by -3.24%, over three months by +24.10% and over the past year by +39.31%.
Current recommended Stop Loss: 14.60 (which is 4.2% or 1.3 ATR below the current price).
AngioDynamics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ANGO.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20 | 31.2% |
P/E Forward = 96.1538
P/S = 1.9971
P/B = 3.8302
P/EG = 1.4079
Revenue TTM = 320.2m USD
EBIT TTM = -36.0m USD
EBITDA TTM = -13.0m USD
Long Term Debt = unknown (none)
Short Term Debt = 1.71m USD (from shortTermDebt, two quarters ago)
Debt = 11.4m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -42.5m USD (calculated: Debt 11.4m - CCE 53.9m)
Enterprise Value = 596.9m USD (639.4m + Debt 11.4m - CCE 53.9m)
Interest Coverage Ratio = -120.4 (Ebit TTM -36.0m / Interest Expense TTM 299k)
EV/FCF = 1000.0x (Enterprise Value 596.9m / FCF TTM 508k)
FCF Yield = 0.09% (FCF TTM 508k / Enterprise Value 596.9m)
FCF Margin = 0.16% (FCF TTM 508k / Revenue TTM 320.2m)
Net Margin = -11.48% (Net Income TTM -36.7m / Revenue TTM 320.2m)
Gross Margin = 54.62% ((Revenue TTM 320.2m - Cost of Revenue TTM 145.3m) / Revenue TTM)
Gross Margin QoQ = 57.06% (prev 52.89%)
Tobins Q-Ratio = 2.23 (Enterprise Value 596.9m / Total Assets 267.2m)
Interest Expense / Debt = 2.62% (Interest Expense 299k / Debt 11.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -28.4m (EBIT -36.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.19 (Total Current Assets 163.4m / Total Current Liabilities 74.7m)
Debt / Equity = 0.07 (Debt 11.4m / totalStockholderEquity, last quarter 170.8m)
Debt / EBITDA = 3.26 (negative EBITDA) (Net Debt -42.5m / EBITDA -13.0m)
Debt / FCF = -83.60 (Net Debt -42.5m / FCF TTM 508k)
Total Stockholder Equity = 174.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.43% (Net Income -36.7m / Total Assets 267.2m)
RoE = -21.01% (Net Income TTM -36.7m / Total Stockholder Equity 174.8m)
RoCE = -18.71% (EBIT -36.0m / Capital Employed (Total Assets 267.2m - Current Liab 74.7m))
RoIC = -16.12% (negative operating profit) (NOPAT -28.4m / Invested Capital 176.4m)
WACC = 6.48% (E(639.4m)/V(650.8m) * Re(6.56%) + D(11.4m)/V(650.8m) * Rd(2.62%) * (1-Tc(0.21)))
Discount Rate = 6.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.08 | Cagr: 1.41%
[DCF] Terminal Value 75.44% ; FCFF base≈508k ; Y1≈510k ; Y5≈540k
[DCF] Fair Price = 1.23 (EV 8.40m - Net Debt -42.5m = Equity 50.9m / Shares 41.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: -31.61 | Revenue CAGR: -1.95% | SUE: 1.72 | # QB: 1
EPS current Quarter (2026-08-31): EPS=-0.11 | Chg30d=-17.17% | Revisions=-40% | Analysts=3
EPS next Quarter (2026-11-30): EPS=-0.08 | Chg30d=-78.37% | Revisions=+0% | Analysts=3
EPS current Year (2027-05-31): EPS=-0.27 | Chg30d=-21.23% | Revisions=+25% | GrowthEPS=-77.8% | GrowthRev=+5.4%
EPS next Year (2028-05-31): EPS=-0.04 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+83.1% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +0% (up=3, down=3)